First-trimester exposure to newer antiretroviral agents and congenital anomalies in a US cohort.

ABSTRACT:

Objective

To characterize associations of exposure to newer antiretroviral medications in the first trimester with congenital anomalies among infants born to persons with HIV in the United States.

Design

Longitudinal cohort of infants born 2012-2022 to pregnant persons with HIV enrolled in the Surveillance Monitoring for ART Toxicities (SMARTT) study.

Methods

First-trimester exposures to newer antiretrovirals (ARVs) were abstracted from maternal medical records. Trained site staff conducted physical exams and abstracted congenital anomalies from infant medical records. Investigators classified anomalies using the Metropolitan Atlanta Congenital Defects Program classification system. The prevalence of major congenital anomalies identified by age one year was estimated

SUBMITTER: Fung K 

PROVIDER: S-EPMC11293967 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature